Kyowa Kirin completed the acquisition of Orchard Therapeutics for $478m.

Kyowa Kirin, a global speciality pharmaceutical company, completed the acquisition of Orchard Therapeutics, a global gene therapy company, for $478m. “We are truly excited about the acquisition of Orchard Therapeutics, a leading provider of HSC gene therapy. This platform offers significant potential to deliver more innovative treatments and breakthrough therapies and aligns with our purpose to deliver life-changing value for people living with rare and complex diseases. Going forward, our companies will build on the extensive experience of Orchard’s gene therapy platform and apply it to under-served indications and diseases where we believe it to be scientifically and clinically differentiated,” Masashi Miyamoto, Kyowa Kirin Representative Director, President and CEO.